Merck Buys Bio-Techne
Merck KGaA agrees to acquire Bio-Techne Corporation in an all-cash transaction valued at approximately $11.3 billion
3 billion, as the German science and technology company seeks to expand its presence across life science research, diagnostics, and bioprocessing markets. Bio-Techne shareholders will receive $73 per share in cash, representing a 36% premium to the company’s one-month volume-weighted average trading price. The deal has already been approved by Bio-Techne’s board and the relevant corporate bodies of Merck KGaA and is expected to close in late 2026 or early 2027, pending shareholder and regulatory approvals.
Read Also: Bio-Techne Stock Upgraded As Analyst Flags Attractive Entry Point Expanding Life Science Capabilities Across Key Growth Areas Merck KGaA said the acquisition aligns with its medium- and long-term strategy focused on high-growth areas, integrated workflows, and innovation through mergers and acquisitions. The combination would unite two life sciences companies with complementary portfolios spanning discovery, translational research, development, testing, and commercial manufacturing. Bio-Techne brings a broad portfolio of recombinant proteins, cytokines, growth factors, antibodies, and immunoassay kits.
The company also owns ProteinSimple, which specializes in automated protein detection and analysis instruments. Additionally, Bio-Techne’s RNAscope and related in situ hybridization technologies are expected to strengthen Merck KGaA’s capabilities in spatial biology and diagnostics. Cell And Gene Therapy Portfolio Set To Gain Scale The acquisition is also expected to enhance Merck KGaA’s position in cell and gene therapy. 9% stake in Wilson Wolf Corporation, a manufacturer of cell culture devices, including the G-Rex product line, and expects to acquire the remaining ownership after 2027 under an existing forward contract.
2 billion in fiscal 2025 net sales. , Switzerland, and China. Merck Expects Synergies And Earnings Benefits Merck KGaA said the transaction will broaden its Process Solutions business by increasing exposure to higher-value reagents, analytics, and advanced research tools while strengthening discovery, development, and manufacturing capabilities. The acquisition will be financed through a combination of existing cash and new debt, while the company expects to maintain an investment-grade credit rating.
11 billion), according to its latest quarterly results. Merck KGaA expects the transaction to be immediately accretive to EBITDA pre margin for both its Life Science business and the broader group after closing. 03 million) expected to be fully realized by that time. 29 during premarket trading on Thursday, according to Pro data.
Photo: Shutterstock Read Also: Imagine Waiting Two Years For Your Tax Refund— More Than 500,000 Identity Theft Victims Are Living That Reality